A A A

Press Releases

Jan 6, 2020

Summary Toggle Alimera Sciences Refinances Its Debt Facility With Solar Capital

Three-year interest-only period Additional $2.5 million available under certain conditions ATLANTA , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of
Dec 4, 2019

Summary Toggle Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019

ATLANTA , Dec. 04, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick Eiswirth , President and Chief
Dec 3, 2019

Summary Toggle Alimera Announces Regulatory Approval for ILUVIEN® in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis

Company continues to execute on its international expansion strategy ATLANTA , Dec. 03, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases,
Nov 26, 2019

Summary Toggle Alimera Sciences to Participate in the 31st Annual Piper Jaffray Healthcare Conference

ATLANTA , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick Eiswirth , President and Chief
Nov 14, 2019

Summary Toggle Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split

ATLANTA , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has filed a certificate of amendment to its restated
Nov 13, 2019

Summary Toggle Alimera Sciences Terminates Equity Purchase Agreement

ATLANTA , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has terminated its $20.0 million common stock purchase
Nov 7, 2019

Summary Toggle Alimera Sciences Announces Board’s Approval of Reverse Stock Split Ratio

ATLANTA , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will effect a one-for-15 reverse stock split (reverse
Nov 5, 2019

Summary Toggle Alimera Sciences to Participate in the 10th Annual Craig-Hallum Alpha Select Conference in New York

ATLANTA , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick Eiswirth , President and Chief
Oct 29, 2019

Summary Toggle Alimera Sciences Announces Third Quarter 2019 Financial Results and Provides Corporate Update

Third Quarter and Recent Company Highlights: Consolidated Net Revenue Up 16% Compared to Third Quarter 2018 International Net Revenue Up 62% Compared to Third Quarter 2018 Launch of ILUVIEN ® for Non-Infectious Posterior Uveitis in U.K. and Germany Approval of ILUVIEN for Non-Infectious Posterior
Oct 25, 2019

Summary Toggle Alimera Sciences Announces Equity Purchase Agreement for up to $20 Million with Lincoln Park Capital

ATLANTA , Oct. 25, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has entered into a $20.0 million common stock purchase